Insight Advisors LLC PA Has $585,000 Position in Novo Nordisk A/S (NYSE:NVO)

Insight Advisors LLC PA lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 34.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,825 shares of the company’s stock after purchasing an additional 1,747 shares during the period. Insight Advisors LLC PA’s holdings in Novo Nordisk A/S were worth $585,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Daiwa Securities Group Inc. purchased a new position in Novo Nordisk A/S during the third quarter worth about $28,000. Capital Performance Advisors LLP purchased a new position in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $42,000. Albion Financial Group UT grew its holdings in shares of Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after acquiring an additional 278 shares in the last quarter. Sound Income Strategies LLC increased its position in shares of Novo Nordisk A/S by 82.1% during the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock valued at $46,000 after acquiring an additional 243 shares during the last quarter. Finally, Hager Investment Management Services LLC bought a new stake in Novo Nordisk A/S during the fourth quarter worth $46,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 3.9 %

Shares of NVO opened at $85.83 on Thursday. The business’s 50-day moving average price is $92.65 and its 200-day moving average price is $112.19. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15. The stock has a market cap of $385.16 billion, a PE ratio of 27.78, a P/E/G ratio of 0.93 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 35.03% and a return on equity of 86.32%. On average, equities analysts forecast that Novo Nordisk A/S will post 3.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NVO has been the subject of several research analyst reports. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.